Skip to content

Effects of oral isotertinoin on folic acid, homocysteine and biochemical and hematological markers in acne vulgaris patients

Effects of oral isotertinoin on folic acid, homocysteine and biochemical and hematological markers in acne vulgaris patients

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012103011316N1
Enrollment
44
Registered
2013-01-08
Start date
2012-10-31
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acne vulgaris.

Interventions

Intervention Treatment of patient would supplement with 0.5 mg/kg/day of oral isotertinoin for 120 days.
Treatment - Drugs
Intervention Treatment of patient would supplement with 0.5 mg/kg/day of oral isotertinoin for 120 days

Sponsors

Lorestan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: patients with acne volgaris on general diet. Exclusion Criteria: patients use others drugs; diabete mellitus; coronary heart disease; metabolic Disease and other serious diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Folic acid. Timepoint: aat the baseline and end of the treatment period (120 day). Method of measurement: by immunoassay method using commercial randox kits.;Homosysteine. Timepoint: at the baseline and end of the treatment period (120 day). Method of measurement: by immunoassay method using commercial Randox kits.

Secondary

MeasureTime frame
Lipid profile. Timepoint: at the baseline and end of the treatment period (120 day). Method of measurement: by autoanalyzer using commercial pars azemon kits.;Gama glutamiltransferase. Timepoint: at the baseline and end of the treatment period (120 day). Method of measurement: by autoanalyzer using commercial pars azemon kits.;Alanin trans aminase. Timepoint: at the baseline and end of the treatment period (120 day). Method of measurement: by autoanalyzer using commercial pars azemon kits.;Aspartat trans aminase. Timepoint: at the baseline and end of the treatment period (120 day). Method of measurement: by autoanalyzer using commercial pars azemon kits.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Ahmadvand

Lorestan University of Medical Sciences

hassan_a46@yahoo.com+98 66 1620 0133

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026